Suppliers / Amoli Organics

Amoli Organics

India Updated 9 July 2026

Amoli Organics is an API manufacturer based in India. It holds 45 active US drug master files. Its filings concentrate with MINSA (CR), NCELS (KZ) and INVIMA (CO). Its GMP standing is certified by CDSCO (India), US FDA and EMA. Its most recent recorded inspection, by US FDA, closed on 4 March 2024 as VAI. Customs aggregates show $2.3M of exports covering 69 molecules to 31 destinations in 2024.

45
active US DMFs
0
valid CEPs
6
registered plants 2 with an FDA FEI number
7
filings across 3 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
2 of 2 confirmed
Inspections
8 of 8 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 4 March 2024 VAI US FDA
  • 12 January 2024 VAI US FDA
  • 20 July 2018 NAI US FDA
  • 31 March 2017 VAI US FDA
  • 20 August 2016 NAI US FDA
  • 12 February 2016 VAI US FDA
  • 24 April 2014 VAI US FDA
  • 30 September 2010 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
shed area gidc vapi vapi 396 195 valsad, India Not on file
Vadodara, India Not on file
Valsad, India 3004810446
Vadodara, India 3007836955
Vadodara, India Not on file
vapivapi 396 195valsad, India Not on file

What they file, and where

Molecule Regulators Docs
Diclofenac SFDA (Saudi Arabia), US FDA 11
Celecoxib SFDA (Saudi Arabia), US FDA 3
Dapagliflozin US FDA 3
Rosuvastatin SFDA (Saudi Arabia), US FDA 3
Venlafaxine SFDA (Saudi Arabia), US FDA 3
Atorvastatin SFDA (Saudi Arabia), US FDA 2
Carbamazepine SFDA (Saudi Arabia), US FDA 2
Desvenlafaxine US FDA 2
Diclofenac Diethylamine SFDA (Saudi Arabia) 2
Levetiracetam SFDA (Saudi Arabia), US FDA 2
Show all 30 molecules on file
Sacubitril/Valsartan US FDA 2
Sildenafil SFDA (Saudi Arabia), US FDA 2
Sitagliptin US FDA 2
Aceclofenac SFDA (Saudi Arabia) 1
Apixaban US FDA 1
Cariprazine US FDA 1
Chlorthalidone US FDA 1
Clotrimazole US FDA 1
Deferasirox US FDA 1
Dimethyl Fumarate US FDA 1
Edoxaban US FDA 1
Empagliflozin US FDA 1
Enzalutamide US FDA 1
Hydrochlorothiazide US FDA 1
Mesalazine US FDA 1
Mirabegron US FDA 1
Olmesartan US FDA 1
Oxcarbazepine US FDA 1
Pirfenidone US FDA 1
Ranolazine US FDA 1

Also appears on these molecule pages

Show 14 more molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
MINSA (CR) 5 None
NCELS (KZ) 1 None
INVIMA (CO) 1 None
CDSCO (India) None 6
US FDA None 2
EMA None 1

Scale

Year Revenue Exports Destinations
2024 Not reported $2.3M 31
2023 Not reported $31.0M 82
2022 Not reported $47.5M 89

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Amoli Organics comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 4 March 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts